Genprex

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company’s lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President and Chief Executive Officer, Rodney Varner, will be participating in two investor conferences in September 2021. CEO Roadshow Webinar Format: Company presentation Presentation Date/Time: September 22, 2021 at 11:00 a.m. ET Access: https://bit.ly/3eoH

Genprex to Participate in September Investor Conferences

Genprex Inc (NASDAQ:GNPX) (FRA:2DE) is gearing up to enroll patients in its Acclaim-1 clinical trial evaluating its lead drug candidate REQORSA in combination with AstraZeneca PLC's (LON:AZN) (NASDAQ:AZN) Tagrisso (osimertinib) for late-stage non-small cell lung cancer following a review from regulator the US Food and Drug Administration (FDA).  The latter has reviewed and confirmed that all comments have been addressed regarding the protocol for the trial, which is an open-label, multi-center Phase 1/2 study testing the drug combined with Tagrisso in those whose disease has progressed after treatment with Tagrisso.

Genprex gears up for patient enrollment in its Acclaim-1 REQORSA trial after FDA feedback

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Food and Drug Administration (FDA) has reviewed and confirmed all comments have been addressed regarding the Company's clinical trial protocol for the Acclaim-1 clinical trial, an open-label, multi-center Phase 1/2 clinical trial evaluating the Company's

Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

AUSTIN, Texas--(BUSINESS WIRE)--Genprex will participate in conferences throughout May 2021.

Genprex to Participate in Upcoming May Investor Conferences

Genprex Inc (NASDAQ:GNPX) said that a major cancer research center in Houston has granted it an exclusive worldwide license for an additional portfolio of six patents and one patent application and related technology for lung cancer treatment.   The newly licensed intellectual property (IP), which expands on a March agreement between both parties, includes methods for treating non-small cell lung cancer (NSCLC) by administration of a TUSC2 therapeutic in conjunction with EGFR inhibitors or other anti-cancer therapies in patients who are predicted to be responsive to TUSC2 therapy, Genprex said.

Genprex in-licenses additional gene therapy technologies to treat non-small cell lung cancer

AUSTIN, Texas--(BUSINESS WIRE)--Genprex expands its oncology franchise and intellectual property portfolio with a license amendment with a major cancer research center.

Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer

Genprex Inc (NASDAQ:GNPX) (FRA:2DE) has received centralized Institutional Review Board (IRB) approval of the clinical trial protocol for its upcoming Acclaim-1 clinical trial in non-small cell lung cancer (NSCLC).  Acclaim-1 is an open-label, multi-center Phase 1/2 clinical trial that combines the company's lead drug candidate, REQORSA immunogene therapy, with AstraZeneca PLC's (LON:AZN) (NASDAQ:AZN) Tagrisso (osimertinib) in patients with late-stage NSCLC with mutated epidermal growth factor receptors (EGFRs) and whose disease progressed after treatment with Tagrisso.

Genprex wins centralized Institutional Review Board approval for its Acclaim-1 clinical trial in non-small cell lung cancer

AUSTIN, Texas--(BUSINESS WIRE)--Genprex receives centralized institutional board approval of its Acclaim-1 clinical trial protocol.

Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer

Genprex Inc (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, announced that it has started clinical trial site recruitment for its upcoming Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (NSCLC). Acclaim-2 is an open-label, multi-center Phase 1/2 clinical trial that combines Genprex's lead drug candidate, REQORSA immunogene therapy, with Merck & Co's Keytruda in patients with “late-stage NSCLC who are low expressors (1% to 49%) of the protein programmed death-ligand 1 (PD-L1),” said the company.

Genprex initiates site recruitment for Acclaim-2 clinical trial for its lung cancer drug REQORSA

AUSTIN, Texas--(BUSINESS WIRE)--Genprex commences clinical trial site recruitment for its combination clinical trial of REQORSA and Tagrisso in NSCLC

Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Genprex will receive the License of the Year award from University of Pittsburgh on April 22 for advances made on gene therapy program in diabetes.

Genprex to Receive Inaugural “License of the Year” Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes

Genprex Inc (NASDAQ:GNPX) said its collaborators have presented positive preclinical data for the combination of REQORSA, the company's proprietary TUSC2 immunogene therapy, in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (NSCLC).  These data were presented in two presentations at the 2021 American Association of Cancer Research (AACR) annual meeting, the company said.

Genprex presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting

AUSTIN, Texas--(BUSINESS WIRE)--Genprex collaborators report new, positive preclinical data for its lead drug candidate, REQORSA, at the 2021 AACR Annual Meeting.

Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting

AUSTIN, Texas--(BUSINESS WIRE)--Genprex' EVP and Chief Operating Officer will present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean

Genprex to Present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean

Genprex Inc (NASDAQ:GNPX) said Tuesday that preclinical data for its lead drug candidate REQORSA, its proprietary TUSC2 immunogene therapy, in non-small cell lung cancer (NSLC), will be featured in two presentations at the six-day virtual annual meeting of the American Association for Cancer Research (AACR 21), starting on April 9. The preclinical data relates to the gene therapy company's TUSC2 immunogene therapy (REQORSA) with chemotherapy and immunotherapies, as well as in combination with targeted therapies to overcome resistance to AstraZeneca's Tagrisso (osimertinib), for the treatment of the NSCLC group of lung cancers.

Genprex to present preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting

AUSTIN, Texas--(BUSINESS WIRE)--Preclinical Data for Genprex' TUSC2 Immunogene Therapy Will Be Featured in Two Presentations at the 2021 AACR Annual Meeting

Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at the 2021 American Association for Cancer Research Annual Meeting

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's President and CEO will present at the Virtual Oncology Investor Conference on March 29

Genprex to Present at the Spring 2021 Oncology Investor Conference on March 29

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will present at upcoming investor conferences in March 2021.

Genprex to Participate in Upcoming March Investor Conferences

Genprex, Inc. (NASDAQ:GNPX) said it has entered into securities purchase agreements with two healthcare-dedicated institutional investors for the purchase and sale of 4,000,000 shares of its common stock at a purchase price of $6.25 per share in a registered direct offering priced at-the-market under Nasdaq rules to raise $25 million. The clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes said no warrants will be issued in connection with the transaction.

Genprex announces $25 million registered direct offering priced at-the-market

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants

Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants

Genprex Inc (NASDAQ:GNPX) announced Monday the formation of a Clinical Advisory Board (CAB) to support its oncology and diabetes development programs.  Comprised of preeminent clinical specialists, the company said the CAB will lead and advise Genprex as it advances its REQORSA immunogene therapy program, including its Acclaim clinical trials in non-small cell lung cancer, and its preclinical diabetes gene therapy program.

Genprex forms Clinical Advisory Board to support its oncology and diabetes development programs

AUSTIN, Texas--(BUSINESS WIRE)--Genprex forms a Clinical Advisory Board.

Genprex Announces Formation of Clinical Advisory Board

AUSTIN, Texas--(BUSINESS WIRE)--Genprex honors World Cancer Day.

Genprex Recognizes World Cancer Day

AUSTIN, Texas--(BUSINESS WIRE)--Genprex issues January 2021 shareholder letter.

Genprex Issues Shareholder Letter and Provides Corporate Update

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will present on February 4 at the Virtual Investor Conference.

News for Genprex Stock (GNPX)